KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Gross Profit (2023 - 2025)

Biocryst Pharmaceuticals' Gross Profit history spans 8 years, with the latest figure at -$8.8 million for Q4 2025.

  • For Q4 2025, Gross Profit fell 107.03% year-over-year to -$8.8 million; the TTM value through Dec 2025 reached $449.9 million, up 2.62%, while the annual FY2025 figure was $855.8 million, 95.18% up from the prior year.
  • Gross Profit reached -$8.8 million in Q4 2025 per BCRX's latest filing, down from $157.2 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $321.2 million in Q4 2023 to a low of -$8.8 million in Q4 2025.
  • Average Gross Profit over 3 years is $134.4 million, with a median of $125.4 million recorded in 2024.
  • The largest YoY upside for Gross Profit was 54.07% in 2025 against a maximum downside of 107.03% in 2025.
  • A 3-year view of Gross Profit shows it stood at $321.2 million in 2023, then tumbled by 60.95% to $125.4 million in 2024, then plummeted by 107.03% to -$8.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Gross Profit are -$8.8 million (Q4 2025), $157.2 million (Q3 2025), and $160.6 million (Q2 2025).